In the flourishing field of cell and gene therapies, a collaboration between Floridian oncology firm Cytovia Therapeutics and French biotech Cellectis (Euronext: ALCLS) is advancing.
Cytovia is developing a unique kind of off-the-shelf therapy, derived from gene-edited Natural Killer (NK) cells, while Cellectis has a portfolio of CAR-T cell candidates in multiple indications.
As a range of new technologies come to fruition, analysts have upped expectations for the therapeutic and commercial potential of cell and gene therapies in recent years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze